← Back to Search

Corticosteroid

Otezla + Enstilar for Psoriasis

Phase 4
Waitlist Available
Led By L.H. Kircik, M.D.
Research Sponsored by Derm Research, PLLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 4, week 16, week 20
Awards & highlights

Study Summary

This study is evaluating whether a combination of two medications may help treat psoriasis.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 4, week 16, week 20
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 4, week 16, week 20 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent of subjects who are clear or almost clear on Physicians Global Assessment at Week 4
Secondary outcome measures
DLQI (dermatology life quality index) at week 4
DLQI at week 16
Itch VAS (visual analogue scale) at week 4 and week 16
+4 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Otezla + EnstilarExperimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Apremilast
FDA approved

Find a Location

Who is running the clinical trial?

Derm Research, PLLCLead Sponsor
17 Previous Clinical Trials
542 Total Patients Enrolled
5 Trials studying Psoriasis
135 Patients Enrolled for Psoriasis
L.H. Kircik, M.D.Principal InvestigatorSkin Sciences, PLLC

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~6 spots leftby Apr 2025